SCHEMBL3436993

SCHEMBL3436993

CC(C)/C=C/CCCCC(=O)Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.43
ALDH1A1 P00352 4/20 0.43
TSHR P16473 1/20 0.43
TP53 P04637 3/20 0.41
ASAH2 Q9NR71 1/20 0.41
CYP1A2 P05177 4/20 0.40
CYP3A4 P08684 3/20 0.40
MAPT P10636 3/20 0.40
KMT2A Q03164 3/20 0.40
HSD17B10 Q99714 3/20 0.40
CYP2C19 P33261 3/20 0.40
MEN1 O00255 2/20 0.40
LMNA P02545 2/20 0.40
ADORA3 P0DMS8 2/20 0.40
ALOX15 P16050 2/20 0.40
PTGS1 P23219 2/20 0.40
CYP2C9 P11712 2/20 0.40
KDM1A O60341 1/20 0.40
NR1I2 O75469 1/20 0.40
ALOX5 P09917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3436995 1.00 TRPV1 (0.43) TRPV1ALDH1A1TSHRTP53ASAH2
SCHEMBL9881033 0.82 TRPV1 (0.44) TRPV1ALDH1A1TP53ASAH2CYP1A2
SCHEMBL2208064 0.82 PPARG (0.57) ALDH1A1CYP1A2MAPTKMT2AHSD17B10
SCHEMBL2208066 0.82 PPARG (0.57) ALDH1A1CYP1A2MAPTKMT2AHSD17B10
SCHEMBL16244201 0.82 CYP1A2 (0.57) TRPV1ALDH1A1TP53ASAH2CYP1A2
SCHEMBL3338606 0.82 PPARG (0.57) ALDH1A1CYP1A2MAPTKMT2AHSD17B10
SCHEMBL4903668 0.82 CYP1A2 (0.57) TRPV1ALDH1A1TP53ASAH2CYP1A2
SCHEMBL2206876 0.80 PPARG (0.60) ALDH1A1CYP1A2CYP3A4MAPTKMT2A
SCHEMBL2206758 0.80 PPARG (0.60) ALDH1A1CYP1A2CYP3A4MAPTKMT2A
SCHEMBL2208737 0.80 PPARG (0.60) ALDH1A1CYP1A2CYP3A4MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025070154-A1 POLYAMIDE RESIN, PHOTOSENSITIVE RESIN COMPOSITION, CURED PRODUCT AND METHOD FOR PRODUCING SAME, AND ELECTRONIC COMPONENT 東レ株式会社 2025-04-03 WO disclosed
US-20240229089-A1 A process for enzymatic synthesis of amides from amines and carboxylic acids or esters XP CHEMISTRIES AB (SE) 2024-07-11 US disclosed
US-20240229089-A1 A process for enzymatic synthesis of amides from amines and carboxylic acids or esters XP CHEMISTRIES AB (SE) 2024-07-11 US disclosed
EP-3336081-B1 NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND USE OF SAID COMPOUND MICROBIAL CHEM RES FOUND (JP) 2019-05-01 EP disclosed
US-10202347-B2 Compound, production method therefor, and use of said compound MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2019-02-12 US disclosed
US-10160725-B2 2018-12-25 US disclosed
EP-3336081-A1 NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND USE OF SAID COMPOUND Microbial Chemistry Research Foundation (JP) 2018-06-20 EP disclosed
EP-3336080-A1 NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND USE OF SAID COMPOUND Microbial Chemistry Research Foundation (JP) 2018-06-20 EP disclosed
US-20180093954-A1 NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND USE OF SAID COMPOUND MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2018-04-05 US disclosed
EP-2963020-B1 NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND USE OF SAID COMPOUND MICROBIAL CHEM RES FOUND (JP) 2017-12-27 EP disclosed
WO-2008147480-A2 HYDROXAMIC ACID DERIVATIVES OF 3-PHENYL PROPIONIC ACIDS USEFUL AS THRAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING PANTHERA BIOPHARNA, LLC. (US) 2008-12-04 WO disclosed
US-20080188566-A1 Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning PAN THERA BIOPHARMA,LLC 2008-08-07 US disclosed
US-20080188566-A1 Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning PAN THERA BIOPHARMA,LLC 2008-08-07 US disclosed
US-20080188566-A1 Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning PAN THERA BIOPHARMA,LLC 2008-08-07 US disclosed
US-20070293703-A1 Preparation and purification of synthetic capsaicin ALGORX PHARMACEUTICALS, INC. (US) 2007-12-20 US disclosed
US-20070293703-A1 Preparation and purification of synthetic capsaicin ALGORX PHARMACEUTICALS, INC. (US) 2007-12-20 US disclosed
EP-0458177-B1 Resin molding composition for preventing gnawing damage by animals NIPPON KAYAKU KK (JP) 1997-07-16 EP disclosed
US-5456916-A Preventing gnawing damage by animals NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1995-10-10 US disclosed
US-5322862-A Microcapsule filled with capsaicine derivative added to thermoplastic resins NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1994-06-21 US disclosed
EP-0458177-A1 Resin molding composition for preventing gnawing damage by animals NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1991-11-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10160725-B2 PGC, HCCS, FABP6 TRPV1 4070/4885ALDH1A1 3112/4885TSHR 4423/4885
US-10202347-B2 Compound, production method therefor, and use of said compound PGC, CYP51A1, WEE1 TRPV1 3494/4885ALDH1A1 2334/4885TSHR 3862/4885
US-20070293703-A1 Preparation and purification of synthetic capsaicin TRPV1, TRPV5, TAC3 TRPV1 1/4885ALDH1A1 2674/4885TSHR 4323/4885
US-20180093954-A1 NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND USE OF SAID COMPOUND PGC, WEE1, CYP51A1 TRPV1 3627/4885ALDH1A1 2234/4885TSHR 4133/4885
US-20080188566-A1 Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning ANTXR2, PAOX, AGXT TRPV1 3399/4885ALDH1A1 517/4885TSHR 2324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.